ClinicalTrials.gg
Not yet recruitingNCT07314814Gen-PoPH-CPSSUpdated Jan 20, 2026

Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension

An observational study in Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH) and Congenital Portosystemic Shunt, sponsored by Prof. Valérie Mc Lin. Not yet recruiting at 1 site in Switzerland. Open to participants aged 1 Day to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Prof. Valérie Mc Lin · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Other
Enrollment
120
Ages
1 Day to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland — 12 open to participants now, 16 under way, 2 of them phase 3. Pulmonary Arterial Hypertension · Switzerland.

Started
2026
with 10 others
Observational
7 of 37
2 open now
Primary completion
2029-08
later than 15 of 15 live
Registered
27th of 37
by date
Lead sponsor
1 of 37
Prof. Valérie Mc Lin

Among the 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland, this one is one of 11 that started in 2026, is one of 7 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 27th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

12 of the 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Day to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland, or all of them as a file.
02

Study summary

Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH).

The goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH.

The long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management.

Children and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.

03

Conditions studied

  • Portopulmonary Hypertension
  • Pulmonary Arterial Hypertension (PAH)
  • Congenital Portosystemic Shunt

Keywords

  • CPSS
  • PoPH
  • PAH
  • Genetic
  • Genomic
  • IRCPSS
04

Who can participate

Ages eligible
1 Day to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patient participant in the IRCPSS, with history of CPSS and PoPH ; both parents of the patient participants; possibly patient siblings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is a participant to the IRCPSS with history of PoPH
  • Trios composed of CPSS PoPH patients and their parents (trios are mandatory)
  • Brother/sister of an enrolled patient
  • Trios accept to provide biological samples (blood), sign the inform consent.
  • Siblings and/or siblings' legal representatives accept to provide biological samples (blood), sign the inform consent.

Exclusion criteria

Exclusion Criteria:

  • Trio condition is not met.
  • No genuine parent-offspring trios (check for medically assisted procreation with donors, and adoption)
  • For siblings, half-brothers or half-sisters are excluded, as well as adopted children, or children issued from medically assisted procreation with donors.
  • Secondary portosystemic shunts
  • The refusal by the patient or the patient's legal representatives to provide biological samples or agree with the proposed procedure or after voluntary withdrawal from the project.
  • The refusal of one of the parents to provide biological samples or to agree with the proposed procedure or after voluntary withdrawal from the project.
05

Study design

Observational model
Family-based
Time perspective
Other
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 30 families

    patient + parents+ siblings

    Genetic: targeted gene panels analysis · Genetic: whole genome analysis

Interventions

  • Genetictargeted gene panels analysis

    The following gene panels will be analyzed : pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.

  • Geneticwhole genome analysis

    Family-based identification of dominant or recessive potentially pathogenic variants.

06

What researchers measure

Primary outcomes

  1. List of variants from targeted analysis of selected gene panels

    presence/absence of pathogenic variants in known genes (pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease) and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.

    Time frame: From February 2026 to February 2029

  2. List of variants from whole genome analysis

    variants identified using family based search for dominant or recessive potentially pathogenic variants

    Time frame: Fron February 2026 to August 2029

07

Study locations

1 site
  • University Hospitals Geneva / University of Geneva
    Geneva, Canton of Geneva 1205, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided — to be determined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Aug 2029, 42 months later.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 42 months is below that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Jan 31, 2030
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314814
Lead sponsor
Prof. Valérie Mc Lin
Responsible party
Prof. Valérie Mc Lin (Prof. Dr. Med., University Hospital, Geneva) — Sponsor-investigator
First posted
Jan 2, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Jan 20, 2026

Study contacts

Prof. Dr. med Valérie A McLIn, MD
Contact
valerie.mclin@hug.ch
+41223724545
Dr. phil. nat Isabelle Schepens, PhD
Contact
isabelle.schepens@hug.ch
+41223724545

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion